Oric Pharmaceuticals
Mr. Iazzetti brings ORIC over 25 years of progressive Human Resources experience spanning workforce planning, Talent Acquisition, HR Operations, Compensation, Employee Engagement and Culture. Most recently, Mr. Iazzetti was the Senior Vice President of Human Resources at Angion Biomedica Corp., where he helped shape the company’s culture while implementing the HR infrastructure to support Angion’s initial public offering in February of 2021. Prior to Angion, Mr. Iazzetti was the interim Vice President of Human Resources at Five Prime Therapeutics. Before joining Five Prime, Mr. Iazzetti led Talent Acquisition at Actelion (acquired by JNJ in 2017) and ZS Pharma (acquired by Astra Zeneca in 2015). His previous experience includes time at Gilead Sciences and Abgenix (acquired by Amgen in 2005). He received his BA in Psychology from Marist College.
This person is not in any teams
This person is not in any offices
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.